Search results for "failure"

showing 10 items of 1977 documents

The role of statins in preventing the progression of congestive heart failure in patients with metabolic syndrome.

2008

Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia- inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in H…

medicine.medical_specialtyHeart diseaseDiseaseBioinformaticsstatin congestive heart failure metabolic sydromeHypolipemiaInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientPharmacologyHeart FailureMetabolic SyndromeClinical Trials as Topicbusiness.industryPublic healthmedicine.diseaseOxidative StressEndocrinologyHeart failureDisease ProgressionMetabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCurrent pharmaceutical design
researchProduct

The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS

2008

Atrial fibrillation (AF) is the most common rhythm disturbance in medical practice and represents a very expensive health problem. AF can be managed with the prevention of thromboembolism and either a rate control of rhythm strategy. As both strategies have important limitations, probably a preventative strategy in patients at risk of developing arrhythmia can be a more attractive option. The renin-angiotensin system (RAS) seems to be involved in the genesis of arrhythmia by the following two mechanisms: 1. the induction of atrial fibrosis and structural remodelling by mitogen-activated protein kinase (MAPK) expression and reduction of collagenase activity; 2. the induction of electrical re…

medicine.medical_specialtyHeart diseaseGenotypeElectric CountershockAngiotensin-Converting Enzyme InhibitorsReview ArticleRenin-Angiotensin Systemrenin-angiotensin system atrial fibrillation ACE-I ARBDiabetes mellitusInternal medicineRenin–angiotensin systemAtrial FibrillationmedicineHumansPharmacology (medical)PharmacologyMitogen-Activated Protein Kinase KinasesEvidence-Based Medicinebiologybusiness.industryAngiotensin IIfungifood and beveragesAtrial fibrillationAngiotensin-converting enzymemedicine.diseaseAngiotensin IIEndocrinologyHeart failureACE inhibitorCardiologybiology.proteinbusinessAnti-Arrhythmia Agentsmedicine.drug
researchProduct

Covid-19 and Congenital Heart Disease: results from a nationwide survey

2020

Background. The pandemic of Novel Coronavirus Disease 2019 (COVID-19) is challenging, given the large number of hospitalized patients. Cardiovascular co-morbidities are linked to a higher mortality risk. Thus, patients with Congenital Heart Disease (CHD) might represent a high-risk population. Nevertheless, no data about them are available, yet. Hence, we conducted a nationwide survey to assess clinical characteristics and outcomes in patients with congenital heart disease affected by COVID-19. Methods and Results. This is a multi-centre, observational, nationwide survey, involving high-volume Italian CHD centres. COVID-19 diagnosis was defined as either &ldquo

medicine.medical_specialtyHeart diseasePopulationcardiovascular complicationslcsh:Medicine030204 cardiovascular system & hematologyChest painArticle03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinecongenital heart disease COVID-19 cardiovascular complicationsmedicinePalpitations030212 general & internal medicineeducationStrokecardiovascular complicationeducation.field_of_studybusiness.industrylcsh:Rcongenital heart disease; COVID-19; cardiovascular complicationsCOVID-19General Medicinemedicine.diseasecongenital heart diseaseHeart failureCohortmedicine.symptombusiness
researchProduct

Treatment and Prophylaxis

1991

Following a stroke, the patient’s neurologic deficit may be most impressive, but his treatment and prognosis depend largely upon accompanying systemic disorders. Acute treatment, for instance, must take into consideration such things as cardiovascular disorders (myocardial infarction, valve defects, arrhythmias, hypertension), disorders of renal function, and diabetes mellitus. The early detection and treatment of such systemic problems can help to prevent complications that would be difficult to control later. Thus, in a patient with latent heart disease hypervolemic therapy with low molecular weight dextran may in fact elicit right heart failure and pulmonary edema instead of helping the …

medicine.medical_specialtyHeart diseasebusiness.industryCerebral infarctionRenal functionmedicine.diseasePulmonary edemaLow molecular weight dextranRight heart failureDiabetes mellitusInternal medicinemedicineCardiologyMyocardial infarctionbusiness
researchProduct

Antigen carbohydrate 125 in heart failure: Not just a surrogate for serosal effusions?

2011

Wehave readwith interest the letter CA-125andheart failure:Deja vu or “still to be seen” by Topatan B and Basaran A [1] where the authors concisely reviewed the current pathophysiological knowledgeof CA125 in heart failure (HF). As discussed by these authors, the pathogenesis of this biomarker's elevation inHF is complex andmultifactorial,with apparently different driven forces. For instances, a proinflammatory stimulus (IL-1, tumour necrosis factor-α, lipopolysaccharide) and mesothelial-induced stress appear thekeymechanisms related to the increaseof this biomarker in HF [1–5]. However, no clear evidence exists in regard to how these two mechanisms differentially participate in CA-125 elev…

medicine.medical_specialtyHeart diseasebusiness.industrymedicine.medical_treatmentRenal functionmedicine.diseasePathophysiologyPeritoneal dialysisProinflammatory cytokinemedicine.anatomical_structurePeritoneumEffusionHeart failureInternal medicinemedicineCardiologyCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-E…

2021

Background: Retrospective analyses of clinical trials indicate that elevated serum uric acid (sUA) predicts poor outcome in heart failure (HF). Uric acid can contribute to inflammation and microvascular dysfunction, which may differently affect different left ventricular ejection fraction (LVEF) phenotypes. However, role of sUA across LVEF phenotypes is unknown. Objectives: We investigated sUA association with outcome in a prospective cohort of HF patients stratified according to LVEF. Methods: Through the Heart Failure Long-Term Registry of the European Society of Cardiology (ESC-EORP-HFLT), 4,438 outpatients were identified and classified into: reduced (= 50% HFpEF) LVEF. Endpoints were t…

medicine.medical_specialtyHeart failure030204 cardiovascular system & hematologyVentricular Function Left03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineInternal MedicinemedicineHumansIn patient030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyRetrospective StudiesInflammationEjection fractionbusiness.industryStroke Volumemedicine.diseasePrognosisClinical trialPhenotypechemistryQuartileHeart failureCohortCardiologyUric acidbusinessUric acid
researchProduct

Blood urea nitrogen to creatinine ratio in acute heart failure: an old concept brought to reality?

2016

Renal dysfunction is one of the most important comorbidities in patients with chronic heart failure (HF) and frequently accentuated in the setting of acute HF (AHF).1 In either context, renal dysfunction has important clinical implications that deserve to be highlighted: (A) the added increase in risk of adverse clinical outcomes2 and (B) at greater degrees of renal failure, well evidenced therapies are lacking and current management remains mostly empirical.1 The pathophysiology of renal dysfunction in AHF is complex, multifactorial and not completely understood, which may potentially explain why patients with worsening renal function (WRF) show mixed clinical response and outcomes.1 An im…

medicine.medical_specialtyHemodynamicsRenal functionContext (language use)030204 cardiovascular system & hematologyBlood Urea Nitrogen03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineIntensive care medicineBlood urea nitrogenHeart FailureCreatininebusiness.industryAcute kidney injuryAcute Kidney Injurymedicine.diseasePathophysiologychemistryCreatinineHeart failureCardiologyCardiology and Cardiovascular MedicinebusinessHeart
researchProduct

Reply

2013

medicine.medical_specialtyHepatologybusiness.industryInternal medicineGastroenterologyLiver failureCardiologyMedicinebusinessmedicine.diseaseThrombosisGastroenterology
researchProduct

Identification of a novel mutation of MTP gene in a patient with abetalipoproteinemia.

2011

Abetalipoproteinemia (ABL), or Bassen-Kornzweig syndrome, is a rare autosomal recessive disorder of lipoprotein metabolism, characterized by fat malabsorption, hypocholesterolemia retinitis pigmentosa, progressive neuropathy and acanthocytosis from early infancy. We describe the clinical and molecular characterization of a 6-month-old infant born of consanguineous, apparently healthy parents from Iran. The patient was hospitalized because of failure to thrive, greasy stool and vomiting. The patient's serum lipid profile, the clinical phenotype and the duodenal histology suggested the clinical diagnosis of ABL. The MTP gene analysis by direct sequencing revealed a novel homozygous mutation (…

medicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaDuodenumSpecialties of internal medicineInternal medicineRetinitis pigmentosamedicineHumansgeneticsFamily HealthMTP gene mutations.ABLHepatologymedicine.diagnostic_testApoB-containing lipoproteins.business.industryAbetalipoproteinemiaInfantAbetalipoproteinemia.Heterozygote advantageGeneral Medicinemedicine.diseaseLipidsAbetalipoproteinemiaFat malabsorptionHypocholesterolemiaEndocrinologyPhenotypeRC581-951Failure to thriveFemaleHypocholesterolemia.medicine.symptomLipid profilebusinessCarrier Proteins
researchProduct

Informed consent in high-risk renal transplant recipients.

2009

Abstract Before performing a clinical, diagnostic, and/or therapeutic action, the doctor is required to provide the patient with a bulk of information defined as informed consent. This expression was used for the first time in 1957 during a court case in California and the two words— informed and consent —are used together to underline the fact that the patient cannot give his or her true consent without first receiving correct information concerning the medical act in question. With regard to the medicolegal aspects governing organ transplants, despite the bulk of detailed work performed by health service workers involved in this surgical field with the aim of preparing adequate informed c…

medicine.medical_specialtyHuman RightsRisk Assessmentinformed consent kidney transplantationHealth servicesInformed consentmedicineHumansEthics MedicalMental CompetencyIntensive care medicineTransplantationInformed Consentbusiness.industryFormalitymedicine.diseaseComorbidityKidney NeoplasmsSurgeryTransplantationSurvival RateSettore MED/18 - Chirurgia GeneraleAction (philosophy)Renal transplantQuality of LifeKidney Failure ChronicSurgeryTransplant surgeonbusinessTransplantation proceedings
researchProduct